Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04546724 |
|
Recruitment Status :
Completed
First Posted : September 14, 2020
Results First Posted : July 25, 2022
Last Update Posted : June 28, 2023
|
Sponsor:
Valneva Austria GmbH
Information provided by (Responsible Party):
Valneva Austria GmbH
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This was a prospective, randomized, double-blinded, multicenter, pivotal clinical study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control was administered as single immunization on Day 1. Overall, 4.128 male and female subjects aged 18 years and above were randomized into the study.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chikungunya Virus Infection | Biological: VLA1553 Biological: Placebo | Phase 3 |
This was a prospective, double-blinded, multicenter, randomized, pivotal Phase 3 study and 4.128 participants aged 18 years or above were randomized in a 3:1 ratio to the live-attenuated CHIKV vaccine candidate (VLA1553) or placebo. The final dose of lyophilized VLA1553 or placebo was administered as a single intramuscular immunization. Subjects in this study were stratified into two age strata of 18 to 64 years and 65 years of age or above. The primary objective of the study was to evaluate the immunogenicity and safety of the final dose of VLA1553 28 days following the single immunization. Immunogenicity evaluations in the immunogenicity subset included the proportion of subjects with seroprotective neutralizing CHIKV antibody titers above a surrogate threshold indicative of protection. The surrogate of protection reasonably likely to predict clinical benefit has been established in non-human primate passive transfer studies using human sera from the Phase 1 study and was supported by sero-epidemiological studies. Safety data collection and immunogenicity were assessed until Month 6.
The first enrolled and randomized 501 subjects comprised the immunogenicity subset.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 4128 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Prevention |
| Official Title: | A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above |
| Actual Study Start Date : | September 17, 2020 |
| Actual Primary Completion Date : | May 19, 2021 |
| Actual Study Completion Date : | October 15, 2021 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: VLA1553
Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose
|
Biological: VLA1553
Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose |
|
Placebo Comparator: Placebo
Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
|
Biological: Placebo
Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo |
Primary Outcome Measures :
- Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination [ Time Frame: on Day 29 after single vaccination ]
Seroprotection rate, based on a surrogate of protection agreed with FDA
Assay used for analysis was based on µPRNT (Micro Plaque Reduction Neutralization Test). Participants at pre-selected sites were included, if they had available Day 1 and Day 29 samples and without major protocol deviations that could impact the immune response.
Secondary Outcome Measures :
- CHIKV-specific Neutralizing Antibody Titers [ Time Frame: Until Day 180 ]CHIKV-specific Neutralizing Antibody Titers on Day 8, and Day 29 Postvaccination as Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) Assay
- Number of Participants With Seroprotective CHIKV Antibody Level [ Time Frame: Until Day 180 ]Seroprotection rate, based on a surrogate of protection agreed with FDA Seroprotective CHIKV Antibody Level Defined as μPRNT (Micro Plaque Reduction Neutralization Test) for Baseline Negative Subjects
- Number of Participants With Seroconversion [ Time Frame: Until Day 180 ]Seroconversion was defined as CHIKV-specific neutralizing antibody titer of ≥ 20 based on µPRNT (Micro Plaque Reduction Neutralization Test) for baseline negative subjects
- Fold "Change" of CHIKV-specific Neutralizing Antibody Titers Compared to Baseline [ Time Frame: until Day 180 ]Fold Change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline
- Number of Participants Reaching an X-fold Change in CHICKV-specific Neutralizing Antibody Titer Compared to Baseline [ Time Frame: until Day 180 ]Number of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline
- Unsolicited AEs [ Time Frame: Until Day 29 ]Number of Participants with Unsolicited Adverse Events
- Solicited Injection Site AEs [ Time Frame: within 10 days post-vaccination ]Number of Participants with solicited injection site reactions
- Solicited Systemic AEs [ Time Frame: within 10 days post-vaccination ]Number of Participants with solicited systemic reactions
- Adverse Events [ Time Frame: until Day 180 ]Number of Participants with any Adverse Events
- Related Adverse Events [ Time Frame: until Day 180 ]Number of Participants with any related Adverse Events
- Serious Adverse Event [ Time Frame: until Day 180 ]Number of Participants with any Serious Adverse Events
- Related Serious Adverse Event [ Time Frame: until Day 180 ]Number of Participants with any Related Serious Adverse Events
- Adverse Event of Special Interest [ Time Frame: within 21 days post-vaccination ]
Number of Participants with any Adverse Event of Special Interest
AESI Definition:
The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration:
- Fever (≥38.0°C [100.4°F] measured orally) and
- Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus [foot plant] and edema of the face and extremities), polyadenopathies; and
- Onset of symptoms 2 to 21 days after vaccination and
- Duration of event ≥3 days.
- Related Adverse Event of Special Interest [ Time Frame: within 21 days post-vaccination ]
Number of Participants with any Related Adverse Event of Special Interest
AESI Definition:
The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration:
- Fever (≥38.0°C [100.4°F] measured orally) and
- Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus [foot plant] and edema of the face and extremities), polyadenopathies; and
- Onset of symptoms 2 to 21 days after vaccination and
- Duration of event ≥3 days.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- 18 years of age or above on the Day of screening
- able to provide informed consent
- generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests
-
for women of childbearing potential:
- practiced an adequate method of contraception during 30 days before screening
- negative serum or urine pregnancy test at screening
- agreed to employ adequate birth control measures for the first three months post-vaccination.
Main Exclusion Criteria:
- CHIKV infection in the past, including suspected CHIKV infection; was taking medication or other treatment for unresolved symptoms attributed to a previous CHIKV infection; or had participated in a clinical study involving an investigational CHIKV vaccine
- acute or recent infection
- Subject tested positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV);
- live virus vaccine within 28 days or inactivated vaccine within 14 days prior to vaccination in this study or planned to receive a vaccine within 28 days or 14 days after vaccination, respectively
- abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered clinically relevant by the Investigator which pose a risk for participation in the study
- medical history of or currently had acute or progressive, unstable or uncontrolled clinical conditions that posed a risk for participation in the study
- history of immune-mediated or clinically relevant arthritis / arthralgia
- history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there had been surgical excision or treatment more than 5 years ago that was considered to have achieved a cure, the subject could be enrolled.
- known or suspected defect of the immune system, such as subjects with congenital or acquired immunodeficiency, including infection with HIV, status post organ transplantation or immuno-suppressive therapy within 4 weeks prior to vaccination.
- history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known contraindications)
- with clinical conditions representing a contraindication to intramuscular vaccination and blood draws
- pregnant or lactating at the time of enrollment
- Donation of blood, blood fractions or plasma within 30 days or received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or planned to donate blood or used blood products until Day 180 of the study
- rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating
- known or suspected problem with alcohol or drug abuse as determined by the Investigator
- any condition that, in the opinion of the Investigator, could compromise the subjects well-being, interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
- committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities)
- Participation in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study
- member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04546724
Locations
Show 44 study locations
Sponsors and Collaborators
Valneva Austria GmbH
Investigators
| Study Chair: | Valneva Clinical Development | Valneva Austria GmbH |
Study Documents (Full-Text)
Documents provided by Valneva Austria GmbH:
Documents provided by Valneva Austria GmbH:
Study Protocol [PDF] March 23, 2021
Statistical Analysis Plan [PDF] January 14, 2022
| Responsible Party: | Valneva Austria GmbH |
| ClinicalTrials.gov Identifier: | NCT04546724 |
| Other Study ID Numbers: |
VLA1553-301 |
| First Posted: | September 14, 2020 Key Record Dates |
| Results First Posted: | July 25, 2022 |
| Last Update Posted: | June 28, 2023 |
| Last Verified: | June 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Valneva Austria GmbH:
|
VLA1553 Chikungunya Virus Infection CHIKV Live-attenuated Chikungunya virus vaccine |
Additional relevant MeSH terms:
|
Virus Diseases Chikungunya Fever Infections Alphavirus Infections |
Arbovirus Infections Vector Borne Diseases Togaviridae Infections RNA Virus Infections |